This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cell Therapeutics' Upcoming FDA Worries

3. How reliable are the response rates in the EXTEND study?

Before I get to this issue, let's review the details and data (per Cell Therapeutics) that came out of the EXTEND study:

The PIX 301 "EXTEND" trial (download the posters here) enrolled 140 patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). The patients, all of whom had received two or more prior therapies, were randomized to receive either pixantrone monotherapy or a doctor's choice of other single-agent chemotherapies.

Cell Therapeutics says the EXTEND study met its primary endpoint, with 25.7% of pixantrone patients achieving a complete response (CR) or an unconfirmed complete response (CRu) compared to 7.1% of patients in the control arm achieving a CR/CRu. The result was statistically significant.

With that as background, watch for how the FDA adjudicates the patients deemed to be unconfirmed complete responders (CRu) because in recent years, at least one influential academic group of lymphoma researchers no longer uses CRu as a valid measurement of disease response. Patients are now characterized as complete responders (CR) or partial responders (PR.)

Six patients treated with pixantrone were deemed unconfirmed complete responders, according to Cell Therapeutics. If some or all of these patients are actually found to be partial responders by the FDA, the 25.7% CR/CRu response rate in the study could fall dramatically. If that happens, the EXTEND study may no longer meet its primary endpoint with statistical significance.

The secondary efficacy endpoints of the EXTEND study were also met, according to Cell Therapeutics. Median progression-free survival for pixantrone patients was 5.6 months compared to median PFS of 2.6 months for patients in the comparator arm -- statistically significant.
3 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CTIC $0.47 -0.06%
AAPL $95.21 0.03%
FB $117.74 0.26%
GOOG $691.47 -0.13%
TSLA $233.38 0.46%


Chart of I:DJI
DOW 17,671.67 -79.24 -0.45%
S&P 500 2,052.89 -10.48 -0.51%
NASDAQ 4,738.5050 -24.7190 -0.52%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs